Zobrazeno 1 - 10
of 290
pro vyhledávání: '"William Z. Potter"'
Publikováno v:
Biomarkers in Neuropsychiatry, Vol 4, Iss , Pp 100029- (2021)
Our current diagnostic methods for treatment planning in Psychiatry and Neurodevelopmental Disabilities leave room for improvement, and null results in clinical trials in these fields may be a result of insufficient tools for patient stratification.
Externí odkaz:
https://doaj.org/article/d2abec5326834a61a3053d230d9071d7
Publikováno v:
Frontiers in Integrative Neuroscience, Vol 13 (2019)
Biological treatment development for syndromal neuropsychiatric conditions such as autism has seen slow progress for decades. Speeding drug discovery may result from the judicious development and application of biomarker measures of brain function to
Externí odkaz:
https://doaj.org/article/8df8fd02aa844154913a8f93f8a4b20d
Autor:
Leah M. Fleming, Daniel C. Javitt, Cameron S. Carter, Joshua T. Kantrowitz, Ragy R. Girgis, Lawrence S. Kegeles, John D. Ragland, Richard J. Maddock, Tyler A. Lesh, Costin Tanase, James Robinson, William Z. Potter, Marlene Carlson, Melanie M. Wall, Tse-Hwei Choo, Jack Grinband, Jeffrey Lieberman, John H. Krystal, Philip R. Corlett
Publikováno v:
NeuroImage: Clinical, Vol 22, Iss , Pp - (2019)
Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces effects in healthy individuals that mimic symptoms associated with schizophrenia. We sought to root these experiences in altered brain function, specif
Externí odkaz:
https://doaj.org/article/11febe31fb8443d1b081e08d479a69f3
Autor:
William Z. Potter
Publikováno v:
Journal of Clinical Psychopharmacology. 42:523-525
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 48(2)
Autor:
Stephen, Zicha, Randall J, Bateman, Leslie M, Shaw, Henrik, Zetterberg, Anthony W, Bannon, Wesley A, Horton, Mike, Baratta, Hartmuth C, Kolb, Iwona, Dobler, Yulia, Mordashova, Ziad S, Saad, David L, Raunig, Emmanouil Manos, Spanakis, Yan, Li, Suzanne E, Schindler, Kyle, Ferber, Carrie E, Rubel, Robert L, Martone, Christopher J, Weber, Rebecca M, Edelmayer, Emily A, Meyers, James G, Bollinger, Erin G, Rosenbaugh, William Z, Potter
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's AssociationREFERENCES.
This report details the approach taken to providing a dataset allowing for analyses on the performance of recently developed assays of amyloid beta (Aβ) peptides in plasma and the extent to which they improve the prediction of amyloid positivity.Alz
Publikováno v:
Biomark Neuropsychiatry
Biomarkers in Neuropsychiatry, Vol 4, Iss, Pp 100029-(2021)
Biomarkers in Neuropsychiatry, Vol 4, Iss, Pp 100029-(2021)
Our current diagnostic methods for treatment planning in Psychiatry and Neurodevelopmental Disabilities leave room for improvement, and null results in clinical trials in these fields may be a result of insufficient tools for patient stratification.
Autor:
William Z. Potter, Alzheimer’s Disease Neuroimaging Initiative, Laetitia Cortes, Mark H. Watson, Daniel Chelsky, Susan Baker, Nandini Raghavan, Daniel S. Spellman, Kelly L. Umaña, Clifford R. Jack, Ondrej Libiger, Rosa M. Canet‐Avilés, Michael C. Biarnes, Yannick-André Breton, Leslie M. Shaw, Angus C. Nairn
Publikováno v:
Alzheimers Dement
Introduction Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development. Methods A targeted, stable isotope, quantitative mass spectromet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d11592cef2afb777517e0bc5355fbea6
https://europepmc.org/articles/PMC9222372/
https://europepmc.org/articles/PMC9222372/
Publikováno v:
Expert Opin Drug Discov
Psychiatric disorders are the leading causes of disability worldwide, and there is an urgent need for new treatments [1]. The exodus of many pharmaceutical companies from psychiatric drug developme...
Autor:
Nina Engelhardt, Cynthia McNamara, Christian Yavorsky, Matthew Masotti, Guillermo Di Clemente, William Z. Potter
Publikováno v:
Therapeutic Innovation & Regulatory Science. 53:176-182
Monitoring the quality of clinical trial efficacy outcome data has received increased attention in the past decade, with regulatory guidance encouraging it to be conducted proactively, and remotely. However, the methods utilized to develop and implem